PT  - JOURNAL ARTICLE
AU  - Tully, Damien C.
AU  - Power, Karen A.
AU  - Sarette, Jacklyn
AU  - Stopka, Thomas J.
AU  - Friedmann, Peter D.
AU  - Korthuis, P. Todd
AU  - Cooper, Hannah
AU  - Young, April M.
AU  - Seal, David W.
AU  - Westergaard, Ryan P.
AU  - Allen, Todd M.
TI  - Validation of Dried Blood Spots for Capturing Hepatitis C Virus Diversity for Genomic Surveillance
AID  - 10.1101/2023.07.06.23292160
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.07.06.23292160
4099  - http://medrxiv.org/content/early/2023/07/07/2023.07.06.23292160.short
4100  - http://medrxiv.org/content/early/2023/07/07/2023.07.06.23292160.full
AB  - Dried blood spots (DBS) have emerged as a promising alternative to traditional venous blood for HCV testing. However, their capacity to accurately reflect the genetic diversity of HCV remains poorly understood. We employed deep sequencing and advanced phylogenetic analyses on paired plasma and DBS samples to evaluate the suitability of DBS for genomic surveillance. Results demonstrated that DBS captured equivalent viral diversity compared to plasma with no phylogenetic discordance observed. The ability of DBS to accurately reflect the profile of viral genetic diversity suggests it may be a promising avenue for future surveillance efforts to curb HCV outbreaks.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute of Drug Abuse (NIDA) grant U24DA044801. Data is based upon data collected and/or methods developed as part of the Rural Opioid Initiative (ROI), a multi-site study with a common protocol developed collaboratively by investigators at eight research institutions and at the National Institute of Drug Abuse (NIDA), the Appalachian Regional Commission (ARC), the Centers for Disease Control and Prevention (CDC), and the Substance Abuse and Mental Health Services Administration (SAMHSA). Primary data collection was supported by grants UG3DA044798, UG3DA044830, UG3DA044831, UG3DA044826 co-funded by NIDA, ARC, CDC, and SAMHSA. The authors thank the other ROI investigators and their teams, the ROI Executive Steering Committee chair, Dr. Holly Hagan, the NIDA Science Officer, Dr. Richard Jenkins, and, particularly, the participants of the individual ROI studies for their valuable contributions. A full list of participating ROI investigators and institutions can be found on the ROI website at http://ruralopioidinitiative.org/studies.html.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study procedures were approved by the Institutional Review Board of Massachusetts General Hospital.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors